Table 3.
Studies that found that TP53 mutations are prognostic for EGFR-mutated NSCLC patients treated with EGFR-TKIs.
| TP53 Status | Number of Patients (Generation of TKI) | Result | Ref. |
|---|---|---|---|
| Non-disruptive mutations | 193 (I) | OS | [105] |
| Any mutation | 131 (I–II) | OS | [106] |
| Any mutation | 116 (I–II) | OS | [107] |
| Exon 8 mutations | 123 (I–II) | DCR, PFS, OS | [108] |
| Exon 8 mutations | 136 (I–II) | OS | [109] |
| Exon 8 mutations | 379 (I–II) | OS | [110] |
| Missense mutations | 60 (I–II) | PFS | [111] |
| Any mutation | 75; 82 (I–II; III) | PFS, PFS | [116] |
| Any mutation | 18 (I) | TTP | [117] |
| Any mutation | 374 (I–II) | TTP | [118] |
| Any mutation | 28 (I) | TTP | [119] |
| Any mutation | 132 (I) | PFS, OS | [121] |
| Any mutation | 71 (I) | TTP, OS | [120] |
| Any mutation | 50 (I) | OS | [122] |
| Any mutationExon 6, 7 mutations | 368 (I) | PFS, OS | [129] |
| Exon 4, 7 mutations | 256 (I) | PFS, OS | [130] |
EGFR: Epidermal Growth Factor Receptor; TKI: Tyrosine Kinase Inhibitor; OS: Overall Survival; DCR: Disease Control Rate; PFS: Progression-Free Survival; TTP: Time-to-progression.